Quantum BioPharma Ltd. (NASDAQ: QNTM) reported unaudited third-quarter results for the period ended Sept. 30, 2026, showing combined cash and digital assets of $12.22 million, up from $4.12 million at year-end 2025 on a basis excluding restricted digital assets. Cash and cash equivalents totaled about $3.56 million, while digital assets reached $8.66 million. The figures matter because management said the holdings are sufficient to support planned operations over the next 12 months, a statement that speaks directly to how long the biopharmaceutical company can fund its clinical work without returning to markets for fresh capital.
The balance sheet improvements extend beyond liquidity. Shareholders' equity rose 91% to $9.77 million, and working capital climbed to $5.47 million from $420,000. Third-quarter operating expenses fell 24% year over year to $3.56 million, and the nine-month net loss narrowed 26% to $17.32 million from $23.25 million. Quantum also cut operating cash use by 21% in the first nine months of 2026 and reduced notes payable to $300,000 after repaying $1 million in debt. For investors in small-cap biotech, tighter spending and a lighter debt load can reduce the risk of dilutive financing.
The most consequential operational development came after quarter-end, when Quantum entered a study start-up agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS for progressive multiple sclerosis. The agreement follows U.S. Food and Drug Administration clearance of the company's Investigational New Drug application in August 2026. Lucid-MS is a patented new chemical entity that the company says has been shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The shift from regulatory clearance to trial implementation is a milestone that investors typically watch closely, because it moves a drug candidate from paperwork into patient-facing testing.
Quantum describes itself as focused on building a portfolio of assets for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., it is developing Lucid-MS as its lead compound. The company also invented UNBUZZD and spun out its over-the-counter version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, along with royalty payments of 7% of sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of rights to develop similar products for pharmaceutical and medical uses.
Readers can review the full press release at https://ibn.fm/byWqL and find company news in its newsroom at https://ibn.fm/QNTM. The announcement was distributed through InvestorWire, part of the Dynamic Brand Portfolio at IBN, which provides editorial syndication to 5,000+ outlets and social media distribution. Terms of use and disclaimers apply as described at https://www.InvestorWire.com/Disclaimer.
